Novavax (NASDAQ:NVAX) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.33) by 6.3 percent. This is a 64.47 percent decrease over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $70.445 million which beat the analyst consensus estimate of $42.133 million by 67.20 percent. This is a 16.64 percent decrease over sales of $84.512 million the same period last year.